- Home
- HPP vs IOVA Comparison
HPP vs IOVA Comparison
Compare HPP & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- IOVA
- Stock Information
- Founded
- HPP 1997
- IOVA 2007
- Country
- HPP United States
- IOVA United States
- Employees
- HPP N/A
- IOVA N/A
- Industry
- HPP Real Estate
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HPP Finance
- IOVA Health Care
- Exchange
- HPP Nasdaq
- IOVA Nasdaq
- Market Cap
- HPP 1.0B
- IOVA 975.1M
- IPO Year
- HPP 2010
- IOVA N/A
- Fundamental
- Price
- HPP $2.73
- IOVA $2.34
- Analyst Decision
- HPP Hold
- IOVA Buy
- Analyst Count
- HPP 10
- IOVA 11
- Target Price
- HPP $3.10
- IOVA $11.90
- AVG Volume (30 Days)
- HPP 4.7M
- IOVA 9.6M
- Earning Date
- HPP 11-05-2025
- IOVA 11-06-2025
- Dividend Yield
- HPP N/A
- IOVA N/A
- EPS Growth
- HPP N/A
- IOVA N/A
- EPS
- HPP N/A
- IOVA N/A
- Revenue
- HPP $792,977,000.00
- IOVA $241,525,000.00
- Revenue This Year
- HPP N/A
- IOVA $68.14
- Revenue Next Year
- HPP $6.49
- IOVA $56.64
- P/E Ratio
- HPP N/A
- IOVA N/A
- Revenue Growth
- HPP N/A
- IOVA 636.99
- 52 Week Low
- HPP $1.78
- IOVA $1.64
- 52 Week High
- HPP $5.02
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- HPP 47.91
- IOVA 54.12
- Support Level
- HPP $2.69
- IOVA $1.97
- Resistance Level
- HPP $2.87
- IOVA $2.17
- Average True Range (ATR)
- HPP 0.11
- IOVA 0.13
- MACD
- HPP -0.01
- IOVA 0.02
- Stochastic Oscillator
- HPP 40.28
- IOVA 90.24
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.